A detailed history of Vr Adviser, LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Vr Adviser, LLC holds 3,458,645 shares of ATXS stock, worth $33.1 Million. This represents 3.94% of its overall portfolio holdings.

Number of Shares
3,458,645
Previous 3,608,645 4.16%
Holding current value
$33.1 Million
Previous $32.8 Million 15.96%
% of portfolio
3.94%
Previous 3.6%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.97 - $12.65 $1.35 Million - $1.9 Million
-150,000 Reduced 4.16%
3,458,645 $38.1 Million
Q1 2024

May 15, 2024

BUY
$6.99 - $16.69 $2.68 Million - $6.39 Million
382,839 Added 11.87%
3,608,645 $50.8 Million
Q4 2023

Feb 14, 2024

BUY
$4.42 - $8.06 $14.3 Million - $26 Million
3,225,806 New
3,225,806 $24.8 Million
Q2 2022

Aug 15, 2022

SELL
$2.46 - $6.96 $1.33 Million - $3.75 Million
-538,999 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$7.32 - $12.9 $3.95 Million - $6.95 Million
538,999 New
538,999 $4.77 Million

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $145M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Vr Adviser, LLC Portfolio

Follow Vr Adviser, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vr Adviser, LLC with notifications on news.